Drug name
Last update: Oct 2026VK2735
Developer(s)
Drug information
Not provided
VK2735; VK-2735
None (investigational)
Biotherapeutic
GLP-1 / GIP dual receptor agonist (incretin mimetic). Synthetic peptide co-agonist of the GLP-1 and GIP receptors; same mechanistic class as tirzepatide.
Active / In Development (Phase 1/2/3) — Phase 3 VANQUISH-1 (obesity/overweight without T2DM, approx. 4,650 enrolled) and VANQUISH-2 (obesity/overweight with T2DM, approx. 1,000 enrolled) fully enrolled; 78-week primary endpoint; primary completion estimated July 2027.
VK2735 (SQ) is the once-weekly subcutaneous injectable formulation of VK2735, an investigational synthetic peptide dual agonist of the GLP-1 and GIP receptors developed by Viking Therapeutics. A single-dose half-life of approximately 170 to 250 hours (about 7 to 10 days) supports once-weekly dosing. In the 13-week Phase 2 VENTURE trial, weekly doses of 2.5 to 15 mg produced 9.1% to 14.7% mean weight loss vs 1.7% with placebo, without a plateau. The formulation is in Phase 3 (VANQUISH programme) at 7.5, 12.5 and 17.5 mg weekly for weight management in adults with obesity or overweight, with and without type 2 diabetes. Viking has contracted CordenPharma for commercial-scale API and autoinjector and vial/syringe supply. Not approved in any country.
Unknown
Unknown
Therapeutic area(s)
- Obesity / Weight Management : "Obesity / Weight Management, including in people with T2DM"
- Treatment
Administration route
Subcutaneous
Associated long-acting platforms
subcutaneous peptide formulation; composition not publicly disclosed
Use of drug
- Self-administered
- To be determined
- Weekly
- Monthly
- Every 2 weeks
Dosage
Not established. Phase 3: once-weekly SC injection titrated to 7.5, 12.5 or 17.5 mg for 78 weeks (schedule not disclosed). VK2735-102 used 1.25 mg week 1, 2.5 mg week 2, then increments every 2W
Not provided
Not provided
Not provided
Not provided
Not provided
Additional information
Developer(s)
Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on novel therapies for metabolic and endocrine disorders. Its pipeline includes the GLP-1/GIP dual receptor agonist VK2735 (subcutaneous and oral formulations), the amylin receptor agonist VK3019 and the thyroid hormone receptor beta agonist VK2809.
Drug structure
Scale-up and manufacturing prospects
Multi-year CordenPharma agreement (March 2025): multiple metric tons of API per year and an annual commitment of 100 million autoinjectors plus 100 million vial and syringe products for the SC formulation on dedicated lines; USD 150 million prepayments over 2025 to 2028; expandable at Viking's option.
Not provided
Not provided
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Commercial presentations planned as autoinjector and vial/syringe (CordenPharma agreement, March 2025). Device used in clinical trials not disclosed.
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL